A synthetic peptide that acts as an antagonist of the NRP1 transmembrane domain (pTM-NRP1) reduces the growth of C6 GBM tumors in orthotopic and heterothopic in vivo models in rats and nude mice by inhibiting GBM cell proliferation and migration in addition to angiogenesis [95]. Here, NRP1 is linked to glioblastoma.